期刊文献+

治疗2型糖尿病的非胰岛素类药物的研究进展 被引量:24

Research progress in non-insulin drugs used for treating type 2 diabetes
原文传递
导出
摘要 2型糖尿病是一种慢性代谢障碍性疾病,呈进行性发展,很难治愈,占糖尿病的90%以上。目前治疗该病的药物有很多,包括传统药物如磺脲类、格列奈类、噻唑烷二酮类、双胍类和α-葡萄糖苷酶抑制剂,以及近些年出现的新作用机制药物如GLP-1受体激动剂、DDP-IV抑制剂和SGLT2抑制剂。对上述各类药物的研究情况进行综述。 Type 2 diabetes is a kind of chronic metabolic disorders and progressive diseases difficult to cure,which is accounting for more than 90% of the diabetes.Currently,there are a lot of drugs for the treatment of type 2 diabetes,including the traditional drugs such as sulfonylureas,glinides,thiazolidinediones,biguanides,and α-glucosidase inhibitor,and drugs with new mechanism developed in recent years,such as GLP-1 receptor agonist,DDP-IV inhibitor,and SGLT2 inhibitors.This article reviewed the research and development of the above types of drugs.
出处 《现代药物与临床》 CAS 2013年第2期108-113,共6页 Drugs & Clinic
关键词 2型糖尿病 GLP-1受体激动剂 DDP-IV抑制剂 SGLT2抑制剂 研发趋势 type 2 diabetes GLP-1 receptor agonist DDP-IV inhibitor SGLT2 inhibitor research and development trends
  • 相关文献

参考文献20

  • 1莫一菲,周健,贾伟平.国际糖尿病联盟2011~2021年全球糖尿病计划解读[J].中国医学前沿杂志(电子版),2012,4(9):20-23. 被引量:17
  • 2Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. NEngl JMed, 2010, 362(12): 1090-1101.
  • 3Citeline, Inc. Pipeline. [DB/OL]. [2013-03-12]. http://pipeline.citeline.congCpLogin.aspx.
  • 4金晶,叶菲.新型餐后血糖调节剂——格列奈类药物的研究进展[J].国外医学(药学分册),2007,34(1):44-47. 被引量:9
  • 5Pouwels K B, van Grootheest K. The rosiglitazone decision process at FDA and EMA. What should we learn? [J] IntJRisk SafMed, 2012, 24(2): 73-80.
  • 6Colmers I N, Bowker S L, Majumdar S R, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis [J]. CMAJ, 2012, 184(12): E675-683.
  • 7Bodmer M, Meier C, Kraenzlin M E, et al. Risk of fractures with glitazones: a critical review of the evidence to date [J]. Drug Saf 2009, 32(7): 539-547.
  • 8Riche D M, King S T. Bone loss and fracture risk associated with thiazolidinedione therapy [J]. Pharmacotherapy, 2010, 30(7): 716-727.
  • 9Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPAR7 agonists: time for a reassessment [J]. Trends Endocrinol Metab, 2012, 23 (5): 205 -215.
  • 10The Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study [J]. Diabetes Care, 2012, 35(4): 731-737.

二级参考文献34

  • 1焦凯.餐时胰岛素促泌剂瑞格列奈作用特点与临床应用[J].实用糖尿病杂志,2005,1(3):59-60. 被引量:17
  • 2Plosker GL, Figgitt DP. Repaglinide:a pharmacoeconomic review of its use in type 2 diabetes mellitus [ J ]. Pharmacoeconomics,2004, 22(6) :389 -411.
  • 3David S. Importance of postprandial glucose control [ J ]. South Med J, 2001,94(8) :804 -809.
  • 4Bickle JF. Meglitinide analogues: a review of clinical data focused on recent trials[J]. Diabetes Metab, 2006, 32(2) :113 -120.
  • 5Tatro DS. Drug facts and comparisons[M]. 58th Edition. St Louis: Wolters Kluwer Health, 2004:657 - 659.
  • 6Hu S, Boettcher BR, Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide [ J ]. Diabetologia,2003, 46( Supp 1 ) : M37 - M38.
  • 7Hollander PA, Schwarz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes[J]. Diabetes Care, 2001, 24(6) :983 -988.
  • 8kishikawa H, Okada Y, Kanda K,et al. Indication for nateglinide in type 2 diabetes mellitus[J]. JUOEG, 2005, 27(2):179-188.
  • 9Taki H, Maki T, Iso T, et al. Postmarketing study of nateglinide in Japan : treatment of medication-naive patients with type 2 diabetes[J]. Adv Ther, 2005, 22(6) :621 -635.
  • 10Tentolouris N, Boutati E, Karambakalis N, et al. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation , and fibrinolysis [ J ]. Nutr Metab Cardivasc Dis, 2005, 15( 1 ) :6 - 12.

共引文献60

同被引文献305

引证文献24

二级引证文献137

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部